News | ECG | December 01, 2022

HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms

Annalise.ai and Nuance announced that the global medical imaging AI company has joined the Nuance Precision Imaging Network (PIN), connecting Annalise.ai workflow orchestration and diagnostic support solutions to over 12,000 healthcare facilities worldwide.

December 1, 2022 —  Heart Test Laboratories, Inc. d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced that it has entered into a multi-year collaboration agreement with Rutgers University (Rutgers), one of America’s leading public research universities.   

HeartSciences and Rutgers will collaborate to develop AI-based ECG algorithms, which are expected to accelerate HeartSciences’ product development pipeline and further expand the clinical value of an ECG for low-cost detection of heart disease. Partho P. Sengupta, MD, MBBS, FACC, Professor and the Chief of Division of Cardiology at Rutgers Robert Wood Johnson Medical School and the Robert Wood Johnson University Hospital, will serve as Rutgers’ Principal Investigator. These collaboration efforts will be focused on leveraging the extensive clinical data compiled at Rutgers. The collaboration agreement follows HeartSciences’ recent participation and demonstration of the MyoVista at the Inauguration Ceremony of the Center for Innovation at the Rutgers and Robert Wood Johnson University Hospital in September 2022. The new collaborative relationship will operate out of the new Rutgers Robert Wood Johnson, Center for Innovation. 

Dr. Sengupta stated, “We look forward to strengthening our existing relationship with HeartSciences for innovating in the important area of leveraging AI to expand the clinical capabilities of an ECG. AI is playing an important role in developing and advancing innovations in cardiology and has demonstrated significant potential for enhancing electrocardiography to improve heart disease detection, while reducing overall healthcare costs.” 

Andrew Simpson, CEO of HeartSciences, stated, “We are excited and honored to enter a collaboration with Dr. Sengupta and Rutgers University. Dr. Sengupta is a globally respected figure in the field of cardiology, including the application of technology to accelerate innovation in the field of cardiology.  We have worked with Dr. Sengupta and his team in the past, with multiple published studies using MyoVista technology. This collaboration formalizes a multi-year arrangement with Rutgers, which we believe will significantly accelerate our product development pipeline of new ECG algorithms for front-line physicians and other healthcare providers.  There are millions of ECGs conducted every week and this collaboration reaffirms HeartSciences’ position at the leading edge of bringing new clinical capabilities to the ECG.” 

For more information: https://www.heartsciences.com 

Find more RSNA22 coverage here  


Related Content

News | Cardiovascular Clinical Studies

June 7, 2023 — The U.S. Food and Drug Administration (FDA) has announced the availability of a draft guidance with ...

Home June 07, 2023
Home
News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
Home
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
Home
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
Home
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
Subscribe Now